These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36658818)

  • 1. Structural insights into the CRISPR-Cas-associated ribonuclease activity of Staphylococcus epidermidis Csm3 and Csm6.
    Zhao Y; Wang J; Sun Q; Dou C; Gu Y; Nie C; Zhu X; Wei Y; Cheng W
    Sci Bull (Beijing); 2018 Jun; 63(11):691-699. PubMed ID: 36658818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the endoribonuclease activity of the type III-A CRISPR-associated protein Csm6.
    Niewoehner O; Jinek M
    RNA; 2016 Mar; 22(3):318-29. PubMed ID: 26763118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cyclic oligoadenylate synthesis by the
    Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
    RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
    Takeshita D; Sato M; Inanaga H; Numata T
    J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6.
    Garcia-Doval C; Schwede F; Berk C; Rostøl JT; Niewoehner O; Tejero O; Hall J; Marraffini LA; Jinek M
    Nat Commun; 2020 Mar; 11(1):1596. PubMed ID: 32221291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Csm6 ribonuclease by cyclic nucleotide binding: in an emergency, twist to open.
    McQuarrie S; Athukoralage JS; McMahon SA; Graham S; Ackermann K; Bode BE; White MF; Gloster TM
    Nucleic Acids Res; 2023 Oct; 51(19):10590-10605. PubMed ID: 37747760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of allosteric activation of the CRISPR ribonuclease Csm6 by cyclic tetra-adenylate.
    Du L; Zhu Q; Lin Z
    EMBO J; 2024 Jan; 43(2):304-315. PubMed ID: 38177499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of III-B CRISPR-Cas systems in archaea.
    Zhang Y; Lin J; Feng M; She Q
    Emerg Top Life Sci; 2018 Dec; 2(4):483-491. PubMed ID: 33525825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the Csm3-Csm4 subcomplex in the type III-A CRISPR-Cas interference complex.
    Numata T; Inanaga H; Sato C; Osawa T
    J Mol Biol; 2015 Jan; 427(2):259-73. PubMed ID: 25451598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA
    Jia N; Jones R; Yang G; Ouerfelli O; Patel DJ
    Mol Cell; 2019 Sep; 75(5):944-956.e6. PubMed ID: 31326273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic characterization of antiplasmid immunity through a type III-A CRISPR-Cas system.
    Hatoum-Aslan A; Maniv I; Samai P; Marraffini LA
    J Bacteriol; 2014 Jan; 196(2):310-7. PubMed ID: 24187086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into the CRISPR-Cas-associated ribonuclease activity of Staphylococcus epidermidis Csm3 and Csm6: a step for the development of novel genome editing tool.
    Gu F
    Sci Bull (Beijing); 2018 Jun; 63(11):672-674. PubMed ID: 36658815
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity.
    Rostøl JT; Marraffini LA
    Nat Microbiol; 2019 Apr; 4(4):656-662. PubMed ID: 30692669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants for CRISPR RNA maturation in the Cas10-Csm complex and roles for non-Cas nucleases.
    Walker FC; Chou-Zheng L; Dunkle JA; Hatoum-Aslan A
    Nucleic Acids Res; 2017 Feb; 45(4):2112-2123. PubMed ID: 28204542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of an active type III-A CRISPR effector complex.
    Smith EM; Ferrell S; Tokars VL; Mondragón A
    Structure; 2022 Aug; 30(8):1109-1128.e6. PubMed ID: 35714601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.
    Niewoehner O; Garcia-Doval C; Rostøl JT; Berk C; Schwede F; Bigler L; Hall J; Marraffini LA; Jinek M
    Nature; 2017 Aug; 548(7669):543-548. PubMed ID: 28722012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A ruler protein in a complex for antiviral defense determines the length of small interfering CRISPR RNAs.
    Hatoum-Aslan A; Samai P; Maniv I; Jiang W; Marraffini LA
    J Biol Chem; 2013 Sep; 288(39):27888-97. PubMed ID: 23935102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural principles of CRISPR-Cas enzymes used in nucleic acid detection.
    Das A; Goswami HN; Whyms CT; Sridhara S; Li H
    J Struct Biol; 2022 Mar; 214(1):107838. PubMed ID: 35123001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coupling of ssRNA cleavage with DNase activity in type III-A CRISPR-Csm revealed by cryo-EM and biochemistry.
    Guo M; Zhang K; Zhu Y; Pintilie GD; Guan X; Li S; Schmid MF; Ma Z; Chiu W; Huang Z
    Cell Res; 2019 Apr; 29(4):305-312. PubMed ID: 30814678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.